Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer

Human Pathology

Volumn 66, Issue , 2017, Pages 1-9

  Shimada, Yoshifumi ^a   Yagi, Ryoma ^a   Kameyama, Hitoshi ^a   Nagahashi, Masayuki ^a   Ichikawa, Hiroshi ^a   Tajima, Yosuke ^a   Okamura, Takuma ^a   Nakano, Mae ^a   Nakano, Masato ^a   Sato, Yo ^b   Matsuzawa, Takeaki ^b   Sakata, Jun ^a   Kobayashi, Takashi ^a   Nogami, Hitoshi ^c   Maruyama, Satoshi ^c   Takii, Yasumasa ^c   Kawasaki, Takashi ^c   Homma, Kei ichi ^c   Izutsu, Hiroshi ^d   Kodama, Keisuke ^d   Ring, Jennifer E ^e   Protopopov, Alexei ^e   Lyle, Stephen ^e,f   Okuda, Shujiro ^a   Akazawa, Kohei ^a   Wakai, Toshifumi ^a   more..

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^c NIIGATA CANCER CENTER HOSPITAL   (Japan)

^d DENKA COMPANY LIMITED   (Japan)

^e KEW Group   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Colorectal cancer; Comprehensive genomic sequencing; Fluorescence in situ hybridization; HER2; Immunohistochemistry; Next generation sequencing

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CODON; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PERSONALIZED MEDICINE; RETROSPECTIVE STUDY; BIOPSY; CHEMISTRY; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; GENE AMPLIFICATION; GENETIC PREDISPOSITION; GENETICS; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; REPRODUCIBILITY;

AGED; BIOMARKERS, TUMOR; BIOPSY; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE AMPLIFICATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA;

EID: 85021237279     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2017.02.004     Document Type: Article

References (34)

1. Popescu, N.C., King, C.R., Kraus, M.H., Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4 (1989), 362–366.
2. Graus-Porta, D., Beerli, R.R., Daly, J.M., Hynes, N.E., ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16 (1997), 1647–1655.
3. Martin, V., Cappuzzo, F., Mazzucchelli, L., Frattini, M., HER2 in solid tumors: more than 10 years under the microscope; where are we now?. Future Oncol 10 (2014), 1469–1486, 10.2217/fon.14.19.
4. Gajria, D., Chandarlapaty, S., HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11 (2011), 263–275, 10.1586/era.10.226.
5. Slamon, D.J., Godolphin, W., Jones, L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 12 (1989), 707–712.
6. Tapia, C., Glatz, K., Novotny, H., et al. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol 20 (2007), 192–198.
7. Scholl, S., Beuzeboc, P., Pouillart, P., Targeting HER2 in other tumor types. Ann Oncol 12 (2001), S81–S87.
8. Valabrega, G., Montemurro, F., Aglietta, M., Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18 (2007), 977–984.
9. Ross, J.S., Slodkowska, E.A., Symmans, W.F., Pusztai, L., Ravdin, P.M., Hortobagyi, G.N., The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14 (2009), 320–368, 10.1634/theoncologist.2008-0230.
10. Bang, Y.J., Van Cutsem, E., Feyereislova, A., et al., ToGA Trial Investigators, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376 (2010), 687–697, 10.1016/S0140-6736(10)61121-X.
11. Kapitanović, S., Radosević, S., Kapitanović, M., et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112 (1997), 1103–1113.
12. Ooi, A., Takehana, T., Li, X., et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 17 (2004), 895–904.
13. Al-Kuraya, K., Novotny, H., Bavi, P., et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 60 (2007), 768–772.
14. Drebber, U., Madeja, M., Odenthal, M., et al. β-Catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis. Int J Colorectal Dis 26 (2011), 1127–1134, 10.1007/s00384-011-1213-9.
15. Ingold Heppner, B., Behrens, H.M., Balschun, K., et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer 111 (2014), 1977–1984, 10.1038/bjc.2014.483.
16. Seo, A.N., Kwak, Y., Kim, D.W., et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One, 9, 2014, e98528, 10.1371/journal.pone.0098528.
17. Song, Z., Deng, Y., Zhuang, K., Li, A., Liu, S., Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas. Int J Clin Exp Pathol 7 (2014), 4454–4460.
18. Valtorta, E., Martino, C., Sartore-Bianchi, A., et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol 28 (2015), 1481–1491, 10.1038/modpathol.2015.98.
19. Bertotti, A., Migliardi, G., Galimi, F., et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1 (2011), 508–523, 10.1158/2159–8290.CD-11-0109.
20. Bensch, F., van Rooijen, J.M., Schröder, C.P., Reyners, A.K., A 21-year-old patient with a HER2-positive colorectal cancer. Gastroenterology 148 (2015), 20–21, 10.1053/j.gastro.2014.09.046.
21. Sartore-Bianchi, A., Trusolino, L., et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17 (2016), 738–746, 10.1016/S1470–2045(16)00150–9.
22. Wolff, A.C., Hammond, M.E., Hicks, D.G., et al., American Society of Clinical Oncology, College of American Pathologists, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31 (2013), 3997–4013.
23. Hanna, W.M., Rüschoff, J., Bilous, M., et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 27 (2014), 4–18, 10.1038/modpathol.2013.103.
24. Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
25. Edge, S.B., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., Trotti, A., AJCC cancer staging manual. 7th ed., 2010, Springer, New York, NY.
26. Kitano, Y., Umemura, S., Ohbayashi, H., Takenaga, M., Osamura, R.Y., Assessment of a new anti-HER2 monoclonal antibody, SV2-61gamma: a best concordance with HER2 FISH. Appl Immunohistochem Mol Morphol 15 (2007), 389–393.
27. Persons, D.L., Bui, M.M., Lowery, M.C., et al. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. Ann Clin Lab Sci 30 (2000), 41–48.
28. Nagahashi, M., Wakai, T., Shimada, Y., et al. Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. Genome Med, 8, 2016, 136, 10.1186/s13073-016-0387-8.
29. Bosman, F.T., Carneiro, F., Hruban, R.H., Theise, N.D., WHO classification of tumours of the digestive system. 4th ed., 2010, IARC, Lyon.
30. National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology-rectal cancer (version 2. 2015). Available: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf [accessed February 3, 2016].
31. Amado, R.G., Wolf, M., Peeters, M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008), 1626–1634.
32. Kavuri, S.M., Jain, N., Galimi, F., et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 5 (2015), 832–841, 10.1158/2159-8290.
33. Bozzetti, C., Negri, F.V., Lagrasta, C.A., et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 104 (2011), 1372–1376, 10.1038/bjc.2011.121.
34. Rachiglio, A.M., Esposito Abate, R., Sacco, A., et al. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget, 2016, 10.18632/oncotarget.10704.